AbSci to Attend BPI-West 2019
If you have an interest in learning more about AbSci’s expression platform, SoluPro, or would like to hear about AbSci’s novel 12-week cell line optimization workflow, reach out to Kole Krieger to schedule some time to meet. kkrieger@abscibio.com...
AbSci Establishes New Collaboration with Sanofi
“This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We’ve shown SoluProTM can uniquely deliver on this industry need.”
AbSci Appoints Andrew J.S. Jones, D. Phil to Scientific Advisory Board
“It is rejuvenating to be working with a young and energetic company like AbSci. Their exciting technology not only has dramatic development, yield and production speed advantages for manufacture of complex biopharmaceuticals,” – Andrew J.S. Jones, D. Phil
AbSci to attend BIO-Europe 2018, 5th – 7th November 2018, in Copenhagen, Denmark
AbSci to attend the Bio-Europe 2018 conference in Copenhagen, Denmark from 5th – 7th November 2018 If you would like to meet with an AbSci Business Development professional, please email us at partnering at abscibio.com
AbSci Raises Oversubscribed $12M Series C to Fuel Commercialization of Its Groundbreaking Protein Expression Platform
The Series C Round led by Asahi Glass Co., Ltd. “AGC” includes participation from all prior investors (Phoenix Venture Partners, Oregon Venture Fund, WRF Capital, and Souther Co.) and new investors Columbia Ventures Corporation and GreenBridge.